Datapoint: FDA Approves Merck’s Tepmetko for NSCLC Mutation

The FDA last week approved Merck KGaA’s Tepmetko for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations, an aggressive form of the disease which affects between 3% and 4% of NSCLC patients, according to a press release from the drugmaker. The drug will have to face off against Novartis’s Tabrecta, which scored the first-in-class nod in May 2020. Under the pharmacy benefit, Tabrecta currently holds preferred formulary placement for 4% of covered lives, growing to 14% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/8/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: HealthPartners to Launch Insurance Products With Avera

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today